Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models

BACKGROUND: NASH causes a tremendous health care burden in the United States. A glucagon-like peptide-1 agonist, semaglutide (Sema), treatment resulted in hepatic steatosis reduction in clinical trials of NASH. Lysophosphatidic acid receptor 1 antagonists are known to have antifibrotic effects in se...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharjee, Jashdeep, Beaton, Graham, Ravula, Satheesh B., Lee, Suk Joong, Bacon, Kevin B., Jenkinson, Celia P., Warren, Mikako, Tucci, Fabio C., Kohli, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666985/
https://www.ncbi.nlm.nih.gov/pubmed/37994050
http://dx.doi.org/10.1097/HC9.0000000000000323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666985/
https://www.ncbi.nlm.nih.gov/pubmed/37994050
http://dx.doi.org/10.1097/HC9.0000000000000323

Ejemplares similares